Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR‐G719A and Other Uncommon EGFR Mutations

Lignende værker

• Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
  af: Sehgal, Kartik, et al.
  Udgivet: (2020)
• Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
  af: Kartik Sehgal, et al.
  Udgivet: (2020-05-01)
• EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors
  af: Vasconcelos, Pedro E.N.S., et al.
  Udgivet: (2020)
• Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer
  af: Sehgal, Kartik, et al.
  Udgivet: (2018)
• Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% expression in lung adenocarcinoma
  af: Rangachari, Deepa, et al.
  Udgivet: (2017)